Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency caused by mutations in the WAS gene that produce deficient WASp, leading to microthrombocytopenia, eczema, recurrent infections, and increased autoimmunity and malignancy risk. Defective actin cytoskeletal remodeling across hematopoietic cells underlies broad immunologic dysfunction and produces small, fragile platelets subject to splenic clearance. Historically, splenectomy has been used to control life-threatening bleeding by reducing platelet sequestration and destruction, often raising platelet counts above 150 × 10^9/L. However, splenectomy does not correct the underlying immune defect and confers a lifelong increased risk of overwhelming infections, requiring vaccination, lifelong antibiotic prophylaxis, and frequently immunoglobulin replacement. With the advent and maturation of curative modalities—hematopoietic stem cell transplantation (HSCT) and gene therapy—the role of splenectomy has substantially diminished and is now largely limited to specific scenarios such as bridging to HSCT, rescue when curative therapies are inaccessible, or post-transplant intervention for persistent thrombocytopenia. Global inequities in access to HSCT and gene therapy maintain a constrained but clinically relevant role for splenectomy in certain settings. Some outcome details and longer-term impacts on transplant success and survival were not fully reported in the source.
WAS is caused by loss-of-function variants in the WAS gene on Xp11.22 and predominantly affects males. The disease spectrum ranges from classic WAS, with absent WASp expression and severe immuno-hematologic disease, to milder phenotypes such as X-linked thrombocytopenia (XLT) and rarer variants including intermittent thrombocytopenia and X-linked neutropenia (XLN). Clinical manifestations typically appear in infancy, with many patients diagnosed within the first year of life. Genotype–phenotype correlations generally associate missense variants with milder disease and non-missense variants with more severe presentations.
Historically, management strategies included splenectomy and immunoglobulin replacement to reduce bleeding and infection risk. Over decades, curative approaches—initially allogeneic HSCT and more recently gene therapy using evolving vector and genome-editing technologies—have shifted the therapeutic paradigm. HSCT provides both immunologic and hematologic correction; gene therapy approaches have moved from γ-retroviral vectors to lentiviral platforms and precise editing tools. Despite these advances, access remains variable, and disease-related morbidity and mortality persist into adulthood.
WASp operates as a regulator of actin nucleation at immune synapses by integrating signals (e.g., Cdc42, PIP2, tyrosine kinase inputs) that activate the Arp2/3 complex. WASp deficiency impairs actin polymerization and disrupts immune synapse formation, producing defective T-cell receptor signaling, skewing toward Th2 responses, and diminishing CD8+ cytotoxic function. NK cells show impaired immunological synapse formation and reduced cytotoxicity, which can be partially ameliorated by IL-2 in some contexts. Antigen-presenting cells such as dendritic cells have defective podosome formation, migration, and lymph node homing, reducing effective antigen presentation.
B-cell function is compromised through impaired B-cell receptor clustering, calcium signaling, class-switch recombination, and marginal zone B-cell maintenance, leading to poor responses to polysaccharide antigens. Regulatory populations (Tregs and Bregs) are also dysfunctional, contributing to breakdowns in peripheral tolerance and autoimmunity; recovery of regulatory populations has been linked to reduced autoimmune flares after autologous gene therapy, although precise mechanisms remain incompletely defined.
Thrombocytopenia arises from combined defects in production and marked peripheral destruction. WASp-dependent defects in megakaryocyte polarization and proplatelet formation produce small, structurally fragile platelets with membrane instability and elevated intracellular calcium, predisposing to rapid splenic clearance. Immune-mediated mechanisms and hypersplenism further accelerate platelet turnover. This pathophysiology explains why splenectomy reliably increases peripheral platelet counts by removing the major site of clearance, yet simultaneously worsens host defense by eliminating key splenic immune functions.
Although HSCT is the established curative standard and gene therapy is an expanding curative option, access is heterogeneous. Donor availability (including underrepresentation of minority donors in registries), the concentration of transplant centers, high financial costs, travel and caregiver burdens, and insurance and health-system limitations contribute to inequitable access. These disparities persist across and within countries and are not solved solely by expanding donor registries. In many low- and middle-income countries, timely access to HSCT or gene therapy remains limited or absent, making temporizing measures such as splenectomy a pragmatic option in selected circumstances.
Geographic reporting of cases is concentrated in the United States and Europe, with additional reports from East Asia and Australia; this distribution likely reflects reporting bias rather than true disease epidemiology. The source notes these access constraints but does not provide exhaustive global prevalence of unmet need.
Splenectomy produces rapid hematologic improvement by reducing platelet sequestration and immune-mediated destruction. Reported platelet responses often reach counts above 150 × 10^9/L and can substantially reduce bleeding risk. The durability of response is phenotype-dependent: patients with XLT more commonly sustain benefit, whereas relapse of thrombocytopenia occurs in a substantial fraction of classical WAS patients—reported in the source as up to 56% within the first year in some series.
However, splenectomy does not correct systemic immune dysfunction. Loss of splenic marginal zone architecture and macrophage function impairs defense against encapsulated organisms and augments the lifelong risk of overwhelming post-splenectomy infection (OPSI). Consequently, patients require strict vaccination, lifelong antibiotic prophylaxis, and often immunoglobulin replacement. The source emphasizes that these infectious risks meaningfully limit the role of splenectomy as a standalone long-term strategy. Splenectomy is therefore most defensible when used as a temporizing bridge to HSCT or gene therapy in patients with severe, refractory thrombocytopenia; as a rescue option where curative therapies are inaccessible; or in selected post-HSCT scenarios (for example, persistent thrombocytopenia from mixed donor chimerism). The article highlights gaps in long-term outcome data (including effects on subsequent transplant success and overall survival) and variability in reported practice, noting that some outcome details were not fully reported in the source.
The therapeutic landscape for WAS has evolved: curative modalities such as HSCT and gene therapy now offer immunologic and hematologic correction, reducing the indications for splenectomy. Nonetheless, due to persistent global disparities in access to curative care and phenotype-dependent hematologic responses, splenectomy retains a limited, case-by-case role as a bridge to definitive therapy or as a rescue measure. Importantly, the hematologic benefits must be weighed against irreversible infectious risks that accompany splenectomy. The source calls for standardized, evidence-based guidelines to clarify contemporary indications and to ensure splenectomy is reserved for situations where expected benefit outweighs risk. Some specific long-term outcome data and geographic outcome detail were not reported in the source and remain areas for further study.